Inactive Instrument

Vitro Diagnostics, Inc.

VODG

US9285013036

Vitro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022

November 03, 2022 at 05:29 pm

Vitro Biopharma, Inc. reported earnings results for the third quarter and nine months ended July 31, 2022. For the third quarter, the company reported revenue was USD 0.865841 million compared to USD 0.331687 million a year ago. Net loss was USD 2.7 million compared to USD 0.666827 million a year ago. Basic loss per share from continuing operations was USD 0.52 compared to USD 0.52 a year ago.
For the nine months, revenue was USD 3.07 million compared to USD 0.785714 million a year ago. Net loss was USD 4.4 million compared to USD 2.69 million a year ago. Basic loss per share from continuing operations was USD 1.3 compared to USD 1.56 a year ago.

Latest news about Vitro Diagnostics, Inc.

Vitro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	05-31	CI
Vitro Biopharma, Inc. announced that it has received $0.3 million in funding	05-12	CI
Vitro Biopharma, Inc. announced that it has received $0.175 million in funding	04-10	CI
Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	03-14	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	01-29	CI
Vitro Biopharma, Inc. Announces Chief Financial Officer Changes	01-23	CI
Vitro Biopharma, Inc. announced that it has received $1 million in funding	01-09	CI
Vitro Biopharma, Inc. announced a financing transaction	11-15	CI
Vitro Biopharma, Inc. announced that it expects to receive $2 million in funding	11-15	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	23-08-28	CI
Vitro Biopharma, Inc. announced that it has received $0.1 million in funding	23-07-12	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	23-06-13	CI
Vitro Biopharma, Inc. announced that it has received $0.325 million in funding	23-06-12	CI
Vitro Biopharma, Inc. announced that it has received $0.1 million in funding	23-06-04	CI
Vitro Biopharma, Inc. announced that it has received $0.2 million in funding	23-04-13	CI
Vitro Biopharma, Inc. announced that it expects to receive CAD 0.2376 million in funding	23-03-14	CI
Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	23-03-14	CI
Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	23-03-14	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2022	23-01-30	CI
Vitro Biopharma, Inc. Auditor Raises 'Going Concern' Doubt	23-01-29	CI
Vitro Biopharma, Inc. amended terms of the transaction	23-01-22	CI
Vitro Biopharma, Inc. announced a financing transaction	23-01-05	CI
Vitro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022	22-11-03	CI
Vitro Biopharma, Inc. has filed an IPO in the amount of $17.25 million.	22-09-09	CI
Vitro Biopharma Inc. Auditor Raises 'Going Concern' Doubt	22-09-08	CI

Chart Vitro Diagnostics, Inc.

Duration

Period

More charts

Company Profile

Vitro Diagnostics, Inc., doing business as Vitro Biopharma, is engaged in the development, manufacturing and distribution of stem cell products and related tools for use in research, drug discovery and clinical trials. The Company's clinical products include clinical grade MSC-Gro for mesenchymal stem cell (MSC) expansion prior to transplantation; an equine MSC cell line with application to treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, and others; testing and therapies related to endogenous stem cell activation; diagnostic testing of stem cell activation and determination of stem cell functional status, and cell-based assays for discovery of stem cell activation agents and new drugs for the treatment of osteoporosis. The Company offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	+0.82%	91.94B
SAMSUNG BIOLOGICS CO.,LTD.	-1.32%	38.74B
BIOGEN INC.	-12.88%	32.82B
UCB	+64.77%	26.66B
BIOMARIN PHARMACEUTICAL INC.	-16.31%	15.32B
INCYTE CORPORATION	-5.78%	13.3B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.38%	11.65B
ALTEOGEN INC.	+173.10%	10.37B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-49.84%	10.12B

Biopharmaceuticals